Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Cash & Equivalents (2012 - 2026)

Updated

Grace Therapeutics (GRCE) recorded Cash & Equivalents of $21.31 million in fiscal Q2 2027 (quarter ended Sep 30, 2026), up 26.4% from $16.86 million a year earlier and up 54.9% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Cash & Equivalents (2012 - 2026) Analysis & Trends

At the end of FY2026 (ended Mar 31, 2026), Grace Therapeutics reported Cash & Equivalents of $16.98 million, down 23.3% from FY2025.

  • Annual Cash & Equivalents has declined for five straight fiscal years, with a five-year compound annual growth rate of -19.7% (FY2021 to FY2026).
  • Across earlier fiscal years, Cash & Equivalents came in at $22.13 million in FY2025 (-3.8%), $23.01 million in FY2024 (-17.5%), $27.88 million in FY2023 (-8.1%) and $30.34 million in FY2022 (-40.4%).
  • The fiscal Q2 2027 figure is the highest quarterly Cash & Equivalents since fiscal Q4 2025.
  • On a year-over-year basis, Cash & Equivalents rose in four of the last eight quarters, with growth averaging 70.8%.
  • Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 617.2% in fiscal Q1 2027, against a decline of 90.1% in fiscal Q1 2026 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at $13.76 million (Q1 2027), $16.98 million (Q4 2026) and $18.67 million (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 4.89 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 16.91 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 10.77 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 9.55 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - 400.00 Mn
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 7.94 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 6.44 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 1.82 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn - 21.31 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 21.31 Mn
Jun 30, 2026 13.76 Mn
Mar 31, 2026 16.98 Mn
Dec 31, 2025 18.67 Mn
Sep 30, 2025 16.86 Mn
Jun 30, 2025 1.92 Mn
Mar 31, 2025 22.13 Mn
Dec 31, 2024 11.06 Mn
Sep 30, 2024 15.16 Mn
Jun 30, 2024 19.39 Mn
Mar 31, 2024 23.01 Mn
Dec 31, 2023 18.55 Mn
Sep 30, 2023 26.99 Mn
Jun 30, 2023 21.63 Mn
Mar 31, 2023 27.88 Mn
Dec 31, 2022 26.24 Mn
Sep 30, 2022 34.93 Mn
Jun 30, 2022 38.38 Mn
Mar 31, 2022 30.34 Mn
Dec 31, 2021 33.01 Mn
API Access

Grace Therapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GRCE&period=max&api_key=YOUR_API_KEY